Changchun YunSci Biopharmaceutical Co., Ltd.

CloseThis

language

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

required

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

analyze

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

Feature

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

advertise

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

Telephone：0431-80528606

Email：YCHT@yunsci.com

Uphold Integrity · Act with Dedication · Innovate · Achieve Mutual Success

About Us

Pioneering Biopharmaceutical Technologies, Conquering Health Challenges

Changchun YunSci Biopharmaceutical Co. Ltd (referred to as Yunxi Bio), is a key subsidiary under Changchun High-Tech, a publicly listed company (stock code: 000661SZ), and serves as the group’s flagship biopharmaceutical division. The company specializes in the independent research and development, as well as the commercial-scale production, of innovative large-molecule drugs. Established in 2019 with a registered capital of 1.4 billion yuan, Yunxi Bio is headquartered at No. 845 Shengde Avenue, Beihu Science & Technology Development Zone, Changchun City. Committed to leveraging cutting-edge biopharmaceutical technologies to address critical health challenges, the company strives to bring greater hope and vitality to society. Each year, Yunxi Bio will undertake the commercial production of more than 10 innovative drug candidates developed by the group.

2019

Founded in

1.4 billion

Registered Capital

3 +

Core Business Segments: Products and Services

*As of September 1，2025

Innovative R&D

Dedicated to developing innovative drugs that are safe, effective, and reliable.

Innovation is the driving force behind Yunxi Bio's growth. Leveraging its robust R&D expertise and supported by the independent technology platform of Changchun High-Tech Group, the company has established a cutting-edge pipeline spanning monoclonal antibodies, multi-specific antibodies, recombinant protein therapeutics, and advanced biocomputing platforms. Additionally, Yunxi is pioneering next-generation ADC and RDC therapies, including NK-cell-based bispecific antibodies, ensuring both efficiency and quality in molecule development—key factors that are propelling the company’s rapid expansion within the industry.

50 +

R&D Personnel

10 years

Project Experience

10 +

10+ full-cycle CMC programs for innovative drugs each year

8 +

In 2025, undertake ≥8 projects

Talent Team

Capabilities

R&D Platform

News&Media

Constant Innovation, Always Better Service.

In-depth understanding of Contract Development and Manufacturing Organizations: Key Considerations and Practices.

11-07

2025

In-depth understanding of Contract Development and Manufacturing Organizations: Key Considerations and Practices.

Explore key considerations for contract development and manufacturing organizations, helping businesses avoid common pitfalls and enhance efficiency and quality throughout the collaboration process.

11-07

2025

CDMO Industry Case Studies: The Power of Innovation and Collaboration.

Explore success stories in the contract development and manufacturing organization industry, revealing how innovation and collaboration are driving the growth of the pharmaceutical sector.

11-06

2025

IND applications typically consist of three main sections.

To achieve the above objectives, a complete IND application must include detailed documentation, primarily consisting of: 1. Animal pharmacology and toxicology studies Purpose: To evaluate the drug’s effects in living organisms and identify any potential toxicity. Content: This includes pharmacodynamic studies (how the drug works), pharmacokinetic studies (how the body processes the drug—absorption, distribution, metabolism, and excretion)—as well as toxicology assessments (determining the safe dose range, identifying target organ toxicity, etc.). This section provides the core evidence of the drug’s safety.

11-06

2025

What is the role of an IND in the biopharmaceutical industry?

In the biopharmaceutical industry, an IND is a core concept—it serves as the critical legal and regulatory bridge linking preclinical drug research with human clinical trials.

Human Resources

A Better Platform, A Better You.

We have a comprehensive training system and a robust promotion framework, providing you with a broader and more rewarding platform for growth. We look forward to achieving your dreams alongside you and jointly building the company’s ambitious vision.

Base salary

Competitive base salary in the industry

Benefits System

Comprehensive Social insurance and housing fund, plus paid annual leave.

Year-end Incentives

A diversified bonus structure.

Changchun YunSci Biopharmaceutical Co. Ltd

Telephone：0431-80528606
Email：YCHT@yunsci.com
Website：www.yunsci.com
Address：No. 845 Shengde Avenue, Beihu Science and Technology Development Zone, Changchun City

Links:

Kinsey

by:300.cn

COOKIES

COOKIES

Innovative biopharmaceutical technologies to tackle health challenges

Pioneering Biopharmaceutical Technologies, Conquering Health Challenges

Dedicated to developing innovative drugs that are safe, effective, and reliable.

Talent Team

Capabilities

R&D Platform

Constant Innovation, Always Better Service.

A Better Platform, A Better You.

You might also like to inquire

Changchun YunSci Biopharmaceutical Co. Ltd

Sorry，当前栏目暂无内容!

Sorry，The current column has no content!